8:00 am – 8:05 am: Opening Remarks

8:05 am – 8:17 am: Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: A 52-Week Phase 2 Study (NEPTUNE). Stephen Anesi, MD

8:17 am – 8:29 am: Discontinuation of Adalimumab in JIA-associated Uveitis. Nisha Acharya, MD

8:29 am – 9:41 am: TPA: A (New) Tool in the Uveitis Armamentarium. Doran Spencer, MD, PhD

9:41 am – 9:53 am: An Open-Label, Multi-Centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability, and Bioactivity of Subcutaneous Repository Corticotropin Injection in Patients with Scleritis – The ATLAS Study: Preliminary Results. Chris Or, MD

9:53 am – 10:05 am:  A Leaky Argument: Is Inflammation in IRD Uveitis? Nitish Mehta, MD

10:05 am – 10:17 am: An Update on Monitoring and Management of Birdshot Retinochoroidopathy. Peter Y. Chang, MD